HOME >> MEDICINE >> NEWS
New data on the effect of Atacand(R) on NYHA class in a broad spectrum of heart failure patients

Mlndal, Sweden, 9 March 2004 Data presented today at the American College of Cardiology (ACC) annual meeting add weight to the evidence shown in the original publications from the CHARM* Programme of the effects of Atacand (candesartan cilexetil) in chronic heart failure (CHF) patients. The results from further analysis of the data add further support for the CHARM study as a landmark clinical research programme.

Importantly, one analysis1 found that New York Heart Association (NYHA) functional class improved in a broad spectrum of CHF patients treated with Atacand. Of all CHARM patients, 35.4% taking Atacand improved in NYHA functional class, 55.6% remained unchanged and 9% worsened. This compared with 32.5%, 57.5% and 10.3% respectively in the placebo group (p=0.004). These findings were supported by a favourable change in the Overall Treatment Evaluation in the Atacand group compared to the placebo group (p=0.01).

Commenting on this additional analysis, Professor John McMurray, principal investigator in the CHARM-Added study, Glasgow University and Western Infirmary, Glasgow, Scotland, said "Improving symptomatic well-being is a key objective of heart failure treatment. NYHA functional classification is the most widely used and validated measure of symptomatic limitation in CHF. That candesartan has been shown to improve NYHA functional class across the broad spectrum of CHF investigated in the CHARM Programme will have significant implications for clinical practice. These findings are consistent with a reduction in CHF hospitalisations".

A further analysis suggests that the development of atrial fibrillation (AF) in some patients with symptomatic chronic heart failure may also be reduced. Of the 7,601 heart failure patients in CHARM, 72.6% did not have atrial fibrillation (AF) at baseline. This new analysis found that, in the patients randomised to Atacand, new incidence of AF during the trial was 6.5%, compared to 7.9% in the place
'"/>

Contact: Mark Chamberlain
mark.chamberlain@ketchum.com
44-207-611-3649
Ketchum
9-Mar-2004


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. Study shows patch therapy may be as effective as oral medications
3. Chronic pain treatments more effective when taken together, new study shows
4. Geodon effective in psychiatric emergencies; Sharply reduces time in restraints
5. Brain activity prior to treatment flags vulnerability to antidepressant side effects
6. Improving access to healthy food has little effect on diet
7. Storage time and temperature effects nutrients in spinach
8. Costs of antidepressants could have funded effective alternatives
9. New ways to design safer & more effective topical (transdermal) drug delivery announced in the PNAS
10. Government wasting your taxpayer money on ineffective drug cure
11. Neurobehavioral function during coma, stroke rehabilitation effective for elderly

Post Your Comments:
(Date:5/3/2015)... May 03, 2015 NuevaCare announced today ... two upcoming area seminars. The first event will take ... Regional Stroke Conference to be held at The Magnolia ... Wednesday, May 13 during the Dementia Conference to be ... “These seminars offer an excellent opportunity to learn about ...
(Date:5/2/2015)... (PRWEB) May 03, 2015 As one ... of the prestigious Safety and Health Achievement and Recognition ... honored to be chosen by the Illinois Department of ... has achieved and maintained SHARP certification by the Occupational ... 2006, as Essentra has continued to meet or exceed ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ProText Kinetic 2 ... use in Final Cut Pro X. ProText Kinetic 2 ... in Final Cut Pro X . Easily create ... with Pixel Film Studios' ProText Kinetic 2. , Using ProText ... by staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... Liverpool, Ohio (PRWEB) May 02, 2015 ... East Liverpool City Hospital (ELCH) gathered to celebrate improvements ... of River Valley Health Partners (RVHP), had zero acquired ... zero urinary catheter associated infections. ELCH was also recently ... , The management team at ELCH credited the teamwork ...
(Date:5/2/2015)... success that Veatch Dental Consulting has had over the years, ... Shields to the team. With Neida and Alex on board, ... working with dentists to ensure their success. , Neida Miranda ... She was certified as dental assistant from Texas State Technical ... the importance of oral hygiene to patients, Neida was moved ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2
(Date:5/1/2015)... 1, 2015  Boston Scientific Corporation (NYSE: BSX ... momentum and long-term growth strategies at a meeting with ... City . President and Chief Executive Officer ... company has to bring forward meaningful innovation to transform ... deliver shareholder value. "We are focused ...
(Date:5/1/2015)... N.J., May 1, 2015 Cambrex Corporation (NYSE: ... 31, 2015. Highlights , Sales ... increased 27% excluding foreign currency impact, driven by Innovator products ... from $8.4 million in the first quarter of 2014. ... $0.04 in the first quarter last year and Adjusted Diluted ...
(Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
Breaking Medicine Technology:Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20
Cached News: